88 citations · 319 across the 16 of their papers we have counts for
17 papers
Methods for non-proportional hazards in clinical trials: A systematic review
Maximilian Bardo, Cynthia Huber, Norbert Benda +13
For the analysis of time-to-event data, frequently used methods such as the log-rank test or the Cox proportional hazards model are based on the proportional hazards assumption, wh…
Optimal allocation strategies in platform trials
Marta Bofill Roig, Ekkehard Glimm, Tobias Mielke +1
Platform trials are randomized clinical trials that allow simultaneous comparison of multiple interventions, usually against a common control. Arms to test experimental interventio…
Use of Non-concurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion
Rajeshwari Sridhara, Olga Marchenko, Qi Jiang +14
This article summarizes the discussions from the American Statistical Association (ASA) Biopharmaceutical (BIOP) Section Open Forum that took place on December 10, 2020 and was org…
The use of external controls: To what extent can it currently be recommended?
Hans Ulrich Burger, Christoph Gerlinger, Chris Harbron +4
With more and better clinical data being captured outside of clinical studies and greater data sharing of clinical studies, external controls may become a more attractive alternati…
Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment
Marta Bofill Roig, Guadalupe Gómez Melis, Martin Posch +1
For randomized clinical trials where a single, primary, binary endpoint would require unfeasibly large sample sizes, composite endpoints are widely chosen as the primary endpoint.…
Online error control for platform trials
David S. Robertson, James M. S. Wason, Franz König +2
Platform trials evaluate multiple experimental treatments under a single master protocol, where new treatment arms are added to the trial over time. Given the multiple treatment co…